Kepos Capital’s Starling Oncology Warrant STLNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-150,000
Closed -$211K – 673
2021
Q3
$211K Hold
150,000
– – 0.01% 458
2021
Q2
$260K Buy
+150,000
New +$202K 0.02% 379
2021
Q1
– Sell
-57,500
Closed -$112K – 444
2020
Q4
$112K Sell
57,500
-37,500
-39% -$64.7K 0.01% 313
2020
Q3
$161K Buy
+95,000
New +$156K 0.02% 218

Other funds holding STLNW

Kepos Capital's STLNW Position: Q4 2021 in Review

Kepos Capital sold out of Starling Oncology Warrant (STLNW) in Q4 2021, closing a stake of 150,000 shares — an estimated $211K sold.

Kepos Capital first reported a position in STLNW in Q3 2020 and held it in 4 quarters. The position peaked at $260K in Q2 2021. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

  • Kepos Capital reported no remaining Starling Oncology Warrant position as of Q4 2021 after selling out during the quarter.
  • Kepos Capital sold 150,000 Starling Oncology Warrant shares in Q4 2021, an estimated $211K.
  • Kepos Capital first reported a position in Starling Oncology Warrant in Q3 2020 and held it in 4 quarters.
  • Kepos Capital's Starling Oncology Warrant position peaked at $260K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q4 2021.

Based on Kepos Capital's 13F filing for Q4 2021, filed 14 Feb 2022.